USE OF SELECTIVE DOPAMINE D4 RECEPTOR AGONISTS FOR TREATING SEXUAL DYSFUNCTION

1 . A method of treating sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a dopamine D 4 receptor agonist or a pharmaceutically acceptable salt thereof with the proviso that said dopamine D 4 receptor agonist is not 5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol.

2 . A method of treating male sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a dopamine D 4 receptor agonist or a pharmaceutically acceptable salt thereof with the proviso that said dopamine D 4 receptor agonist is not 5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol.

3 . A method of treating female sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a dopamine D 4 receptor agonist or a pharmaceutically acceptable salt thereof with the proviso that said dopamine D 4 receptor agonist is not 5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol.

4 . A method of treating male erectile dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a dopamine D 4 receptor agonist or a pharmaceutically acceptable salt thereof with the proviso that said dopamine D 4 receptor agonist is not 5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol.

5 . A method of treating sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D 4 receptor agonist or a pharmaceutically acceptable salt thereof.

6 . A method of treating male sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D 4 receptor agonist or a pharmaceutically acceptable salt thereof.

7 . A method of treating female sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D 4 receptor agonist or a pharmaceutically acceptable salt thereof.

8 . A method of treating male erectile dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D 4 receptor agonist or a pharmaceutically acceptable salt thereof.

9 . The method of claim 6 wherein said selective dopamine D 4 receptor agonist is N-{[4-(2-cyanophenyl)-1-piperazinyl]methyl}-3-methylbenzamide or a pharmaceutically acceptable salt thereof.

10 . The method of claim 7 wherein said selective dopamine D 4 receptor agonist is N-{[4-(2-cyanophenyl)-1-piperazinyl]methyl}-3-methylbenzamide or a pharmaceutically acceptable salt thereof.

11 . The method of claim 8 wherein said selective dopamine D 4 receptor agonist is N-{[4-(2-cyanophenyl)-1-piperazinyl]methyl}-3-methylbenzamide or a pharmaceutically acceptable salt thereof.

12 . The method of claim 6 wherein said selective dopamine D 4 receptor agonist is 5-fluoro-2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}-1H-indole or a pharmaceutically acceptable salt thereof.

13 . The method of claim 7 wherein said selective dopamine D 4 receptor agonist is 5-fluoro-2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}-1H-indole or a pharmaceutically acceptable salt thereof.

14 . The method of claim 8 wherein said selective dopamine D 4 receptor agonist is 5-fluoro-2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}-1H-indole or a pharmaceutically acceptable salt thereof.

15 . A method of claim 5 wherein said selective dopamine D 4 receptor agonist is 3 fold more selective for the D 4 receptor than for the D 2 receptor.

16 . A method of claim 5 wherein said selective dopamine D 4 receptor agonist is 25 fold more selective for the D 4 receptor than for the D 2 receptor.

17 . A method of claim 5 wherein said selective dopamine D 4 receptor agonist is 50 fold more selective for the D 4 receptor than for the D 2 receptor.

18 . A method of claim 5 wherein said selective dopamine D 4 receptor agonist is 100 fold more selective for the D 4 receptor than for the D 2 receptor.

19 . A method of claim 5 wherein said selective dopamine D 4 receptor agonist is 200 fold more selective for the D 4 receptor than for the D 2 receptor.

20 . A method of claim 5 wherein said selective dopamine D 4 receptor agonist is 300 fold more selective for the D 4 receptor than for the D 2 receptor.

21 . A method of claim 5 wherein said selective dopamine D 4 receptor agonist is 500 fold more selective for the D 4 receptor than for the D 2 receptor.

22 . A method of claim 5 wherein said selective dopamine D 4 receptor agonist is 1000 fold more selective for the D 4 receptor than for the D 2 receptor.

23 . A method of treating sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D 4 receptor agonist or a pharmaceutically acceptable salt thereof wherein said agonist does not cause significant emesis.

24 . A method of treating male sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D 4 receptor agonist or a pharmaceutically acceptable salt thereof wherein said agonist does not cause significant emesis.

25 . A method of treating female sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D 4 receptor agonist or a pharmaceutically acceptable salt thereof wherein said agonist does not cause significant emesis.

26 . A method of treating male erectile dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D 4 receptor agonist or a pharmaceutically acceptable salt thereof wherein said agonist does not cause significant emesis.

27 . A method of treating sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D 4 receptor agonist or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.

28 . A method of treating male sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D 4 receptor agonist or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.

29 . A method of treating female sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D 4 receptor agonist or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.

30 . A method of treating male erectile dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D 4 receptor agonist or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.

31 . A method of treating male erectile dysfunction comprising administering to a mammal in need of such treatment a therapeutically effective amount of one or more selective dopamine D 4 receptor agonists in combination with a phosphodiesterase 5 inhibitor or an adrenoceptor antagonist.